Investigations focused on the resistance profiles of NNRTIs for almost two decades gave rise to the discovery and development of diarylpyrimidine(DAPY)derivatives,such as the clinically approved drugs etravirine(TMC125)and rilpivirine(TMC278)which retain excellent activity against a large panel of HIV-1 mutant strains[1,2].